Last reviewed · How we verify
NCT05818592
Screening for Atrial Fibrillation With Self Pulse Monitoring
NA trial testing Self-Pulse Monitoring in Atrial Fibrillation New Onset in 526 participants. Completed in 31 May 2022.
31 May 2022
Quick facts
| Lead sponsor | University of North Carolina, Chapel Hill |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 526 |
| Start date | 21 September 2020 |
| Primary completion | 31 May 2022 |
| Estimated completion | 31 May 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Self-Pulse Monitoring
Conditions studied
- Atrial Fibrillation New Onset — all drugs for Atrial Fibrillation New Onset →
Sponsor
University of North Carolina, Chapel Hill
Who can join
18 and older, any sex, with Atrial Fibrillation New Onset. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to determine the efficacy of self-pulse monitoring in detecting atrial fibrillation (AF) in adult patients at increased risk of stroke. The main questions it aims to answer are: * Is self-screening an effective modality for diagnosis of AF? * Are there clinical differences and outcomes for patients who self-screen? Eligible participants will be randomized to either the intervention group or control group. The control group will continue with usual standard of care. Participants randomized to the intervention group will be asked to: * View an online educational video to teach them the appropriate way to manually check their pulse for irregularities. * Manually check their pulse for 30 seconds twice daily for 14 days. * Patients who screen positive for irregularities will be sent a 14-day wearable cardiac monitor to assess for underlying arrhythmias. Researchers will compare the intervention group to the control group to see if there are clinical differences and outcomes.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Atrial fibrillation: epidemiology, screening and digital health.
Linz D, Gawalko M, Betz K, Hendriks JM, et al · · 2024 · cited 230× · PMID 38362546 · DOI 10.1016/j.lanepe.2023.100786
Verify or expand the search:
- PubMed search for NCT05818592
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Atrial Fibrillation New Onset
Currently open trials in the same condition.
- NCT05841056 — Short Term Anti-aRrhythmic Therapy for Post-Operative AF in Cardiac Surgery Patients Pilot Trial · Phase 3 · recruiting
- NCT06275503 — STROKESTOP III - Optimized Method for Atrial Fibrillation Screening · NA · recruiting
- NCT06159985 — Effect of Left Posterior Pericardiotomy for the Prevention of POAF · NA · recruiting
- NCT05444335 — Screening for Atrial Fibrillation in Elderly Women Older Than 70 Years · NA · active not recruiting
- NCT05229211 — Tracking Atrial Fibrillation After Intensive Care Admission · recruiting
Other University of North Carolina, Chapel Hill trials
Trials by the same sponsor.
- NCT06841913 — Woodsmoke Exposure, Influenza Infection, and Nasal Immunity · Phase 4 · suspended
- NCT07383428 — The INICIO-Guatemala Study · NA · not yet recruiting
- NCT07528443 — Ultraprocessed Foods in Colombia · NA · not yet recruiting
- NCT07507370 — CARED : A Novel Rapid Treatment Paradigm for Depression · NA · not yet recruiting
- NCT07534254 — Piloting a Generative Artificial Intelligence Chatbot in a Mobile Weight Loss Program · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05818592 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of North Carolina, Chapel Hill
- Last refreshed: 19 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05818592.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing